logo-loader
viewBenitec Biopharma

Benitec Biopharma’s shares ride higher after securing new U.S. patent

Research activities progressing towards new treatment options for hepatitis B.

a doctor sitting in front of a computer
patented gene-silencing technology

Benitec Biopharma Ltd’s (ASX:BLT) shares closed 20% higher on Wednesday after securing a new patent related to its hepatitis B program in the U.S.

The biotechnology company is developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi (or expressed RNAi).

The grant of this U.S. patent is an important addition to Benitec’s intellectual property portfolio and provides protection for advanced stage research activities towards new treatments for hepatitis B.

Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and cancer immunotherapy.

The ddRNAi-based therapeutics are also used for chronic and life-threatening human conditions, including OPMD, head & neck squamous cell carcinoma, retinal based diseases and hepatitis B.

Worldwide, 2 billion people (1 out of 3 people) have been infected with hepatitis B virus and 400 million people have become chronically infected, including 1 to 2 million people in the U.S.

An estimated 1 million people die each year from hepatitis B and its complications worldwide with about 5,000 of those in the U.S.

The company’s shares closed at $0.18 on Wednesday.

Quick facts: Benitec Biopharma

Price: - -

ASX:BLT
Market: ASX
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Jindalee Resources' Lindsay Dudfield talks plans to unlock value at its...

Jindalee Resources Ltd's (ASX:JRL) Lindsay Dudfield discusses with Proactive London's Andrew Scott the plans to advance its McDermitt US lithium project. Back in June they received encouraging metallurgical test-work results from the project which confirmed an increase in lithium head grade...

2 days, 11 hours ago

2 min read